Ozon Pharmaceuticals

Ozon Pharmaceuticals is a Russian manufacturer of pharmaceuticals. The product range is represented in all pharmaceutical niches: traditional low molecular weight pharmaceuticals, production of highly toxic drugs against oncology and complex science-intensive drugs in the field of biotechnology. It produces more than 350 items of finished pharmaceuticals, with an annual output of about 5 billion units.
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Ozon Pharmaceuticals balance sheet

Report period2021 2022 2023 2024
End date of the reporting period
Capitalization, ₽
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Ozon Pharmaceuticals cash flows

Report period2021 2022 2023 2024
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
EBITDA
Adjusted EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

Ozon Pharmaceuticals multipliers

Report period2021 2022 2023 2024
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

Ozon Pharmaceuticals profitability

Report period2021 2022 2023 2024
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
Ozon Pharmaceuticals assets
Ozon Pharmaceuticals cash flows
Ozon Pharmaceuticals dividends
1.03%

Ozon Pharmaceuticals dividend policy

The criterion for dividend payment is the Net Debt / EBITDA ratio. The dividend policy envisages the following scenarios: Net Debt / EBITDA > 3x - no dividends are paid; 2x < Net Debt / EBITDA ≤ 3x - at least 15% of Net Profit; 1x < Net Debt / EBITDA ≤ 2x - at least 25% of Net Profit; 0x < Net Profit / EBITDA ≤ 1x - at least 35% of Net Profit, but not more than 100% of free cash flow; Net Profit / EBITDA = 0x - at least 50% of Net Profit, but not more than 100% of free cash flow.

Ozon Pharmaceuticals shares

TickerNameTypeNominal valueISINPrice
OZPH:RMOzon PharmaceuticalsCommon shareRUB 0.02RU000A109B25RUB 51.11

Ozon Pharmaceuticals bonds

NameIssue sizePriceYield
Ozon 001P-01 (RUB)1,000,000 pcs.95.38%16.03%
Ozon 001P-02 (RUB)700,000 pcs.92%17.27%

Ozon Pharmaceuticals expected events

DateTypeNoteSource
23.05.2025 09:00
Meeting of shareholders
Shareholders will decide on dividends for 2024 year  disclosure.skrin.ru
23.05.2025 10:00
Operating results
Operating results for 3 months of 2025Pictogram of ozonpharm.ru  ozonpharm.ru
23.05.2025 10:00
Financial results
Financial statements for 3 months of 2025 under IFRSPictogram of ozonpharm.ru  ozonpharm.ru
28.05.2025 10:00
Board of directors meeting
Board of Directors will consider dividends for Q1 2025Pictogram of www.tbank.ru  www.tbank.ru
04.06.2025 10:00
Dividends
The last day of purchase for receiving dividends RUB 0.26 per common share for 2024.  disclosure.skrin.ru
19.06.2025 10:00
Dividends
Deadline for payment of dividends RUB 0.26 per common share for 2024.  disclosure.skrin.ru
Share capital structure of Ozon Pharmaceuticals
Ozon Pharmaceuticals news
29.04.2025
Board of Directors of Ozon Pharmaceuticals recommended that dividends be paid for 2024 in the amount of ₽0.26 per ordinary share. The last day of the purchase of securities to receive dividends is June 4, 2025. Dividend yield may amount to 0.48%.
Source: disclosure.skrin.ru
Pictogram next
24.04.2025
Ozone Pharmaceuticals expects revenue growth of at least 25% by the end of 2025, which is above the 10-15% growth forecast for the pharmaceuticals market. Capital investments will amount to ₽3.5-4.5 bln. Main investments will be made in the registration of biotechnological drugs. At the same time, the debt load is planned to remain in the range of 1-1.5x net...
Source: {source} pictogram ozonpharm.ru
Pictogram next
24.04.2025
Ozone Pharmaceuticals' IFRS net profit for 2024 was ₽4.6 billion, up 15% from ₽4 billion in the previous year. Revenue rose 29.6% to ₽25.56 billion versus ₽19.72 billion a year earlier.
Source: {source} pictogram e-disclosure.ru
Pictogram next
17.04.2025
Ozone Pharmaceuticals' RAS net profit for 2024 amounted to ₽2.2 billion, up 2.1 times from ₽1.02 billion in the previous year. Revenue grew 2.8 times to ₽2.92 billion against ₽1.05 billion a year earlier.
Source: {source} pictogram e-disclosure.ru
Pictogram next
All Ozon Pharmaceuticals news
General information
Company nameOzon Pharmaceuticals
Tags#pharmacy, #biotechnology, #ipo2024
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Pharmaceuticals / Pharmaceuticals
Business addressRF, Samarskaya oblast, g. Zhigulevsk, ul. Gidrostroiteley, d. 6
Mailing address445351, Samarskaya oblast, g. Zhigulevsk, ul. Gidrostroiteley, d. 6
Websiteozonpharm.ru
Information disclosuree-disclosure.ru